USNA Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy

03
Cena $14.82
Kapitalizacja Rynkowa (MRQ) $274M
P/E (TTM) -7.1
EPS (TTM) $-2.10
Przychody (TTM) $927M
ROE (TTM) -7.4%
Zakres 52 tyg. $13–$28

USNA Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok

04
zakres
kreski

Granularność słupków dostosowuje się do wybranego okresu — najedź kursorem na wykres, aby zobaczyć otwarcia/maksima/minima/zamknięcia dla danego słupka.

Podziały akcji 3
Data ex-dywidendy Podział Typ
23 listopada 2016 2-for-1 Naprzód
31 października 2003 2-for-1 Naprzód
4 sierpnia 1998 2-for-1 Naprzód

O USANA Health Sciences, Inc. Common Stock Przegląd firmy z Wikipedii

05 · wikidata

USANA Health Sciences, Inc., or USANA, is an American direct sales company based in Salt Lake City, Utah. As of 2021, USANA was the 14th largest direct-selling company in the world by revenue. The company manufactures most of its nutritional products, dietary supplements, and skincare products at a Salt Lake City facility. Its products are sold in 25 countries via a network of independent distributors.

History

In 1992, immunologist and microbiologist Myron Wentz moved his diagnostic testing company, Gull Laboratories, from Salt Lake City to West Valley City, Utah, and spun it into USANA Health Services, a multilevel marketing manufacturer of supplements. Beginning in 1993, Dallin A. Larsen served as USANA's vice president of sales (and later as a consultant to USANA's president and special advisor to the board of directors) before founding the MLM beverage company Monavie in 2005. USANA's products are not available through retail channels, and can only be obtained through one of its brand partnersor by direct order through the company.

On 20 February 2007, Barry Minkow, founder of the Fraud Discovery Institute, distributed a 500-page report to officials at the U.S. Securities and Exchange Commission (SEC), the Federal Bureau of Investigation (FBI), and the Internal Revenue Service (IRS) accusing USANA of operating an illegal pyramid scheme. The SEC conducted an investigation into USANA's business practices in March 2007 and found no evidence of wrongdoing, concluding its inquiry with no enforcement action recommended. Minkow acknowledged that he was shorting USANA's shares, hoping to profit from a drop in the stock price. In April 2007, a class action lawsuit was filed alleging that USANA's common stock had been artificially inflated. In August 2007, USANA was notified by the Securities and Exchange Commission (SEC) that its shares were subject to delisting from the NASDAQ due to its Form 10-Q, and was determined to be in compliance that October.

In January 2008, a shareholder suit was filed with allegations that USANA had misled investors about the sustainability of its growth and business model. The cases were dismissed, and the company was cleared by the U.S. Securities and Exchange Commission after an informal inquiry into the allegations, stating that it did "not intend to recommend any enforcement action by the Commission." Later that year, two Canadian USANA distributors were awarded $7 million in damages for their wrongful dismissal from the company. The firm had terminated their positions in 2003 because it believed the distributor had violated the companies' policies and procedures.

USANA filed suits against Minkow and his company claiming defamation and stock manipulation. USANA dropped the defamation suit and in March 2008 U.S. District Judge Tena Campbell threw out four of the five claims brought by USANA against Minkow ruling that USANA's claims violated California's anti-SLAPP law for suing Minkow for fair criticism and that USANA did not show a reasonable probability of winning on those claims. The remaining charge of stock manipulation was settled in July 2008, when USANA and Minkow reached an undisclosed settlement that included the removal of all USANA-related materials from the Fraud Discovery Institute website, a related Chinese website, and YouTube. Minkow also agreed to never trade in USANA's stock again.

In December 2010, USANA completed the application process to transfer its common stock listing from the NASDAQ National Market System, where it had traded since 1996, to the New York Stock Exchange. The transfer became official at the beginning of 2011. It received drug-establishment registration from the Food and Drug Administration to manufacture over-the-counter drugs later that year. In 2012, 91% of product sales were purchased by associates. The company acquired BabyCare Ltd., a China-based prenatal supplement company, in 2013 and announced plans to build a manufacturing facility in the country.

By 2018, USANA had reported record revenue due to growth in the Asia-Pacific region, though it recorded a 7% drop in net sales during its 2019 annual report. USANA has partnered with HealthCorps on health education for children and, in 2019, the USANA Foundation's Kids Eat program opened a facility to pack and distribute food for childhood hunger in the Utah area. In 2026, the Kids Eat program continued efforts to address childhood food insecurity in Utah by providing food bags to students and allowing businesses, families, and other organizations to sponsor participating schools. It was also announced as the official nutritional partner of the Spartan Race endurance brand in the United States. Its sales for the first quarter of 2020 declined by 2.3 percent compared with 2019 numbers.

The USANA Foundation was founded in 2012 and has provided hundreds of millions of meals in more than 45 countries. Their programs include USANA Kids Eat and the USANA Garden Towers.

In February 2019, the Ministry of Commerce in China suspended operations of all multi-level marketing companies and participants to conduct a 100-day review of the country's health foods industry due to exaggerated advertising claims and questionable products in the unregulated sector. Chinese departments initiated "Hundred Days of Action" to clean up the health market, where 49 products from various companies were revoked, 54 food business licenses of various companies were revoked, 90 business licenses of various companies were revoked, and 465 counterfeit and fake dens were destroyed. 85 companies, including BabyCare Ltd., a USANA subsidiary, signed a declaration to self-discipline and regulate operations, with BabyCare speaking at an event hosted by the Chinese government.

In 2024, USANA acquired a 79% stake in children's health and wellness company Hiya Health in a $260 million transaction, making Hiya a subsidiary of USANA. At the time of the acquisition, Hiya had grown to approximately $100 million in annual sales and offered eight children's health products, including multivitamins, probiotics, iron supplements, and immune support products.

Corporate affairs

Leadership

In 2007, USANA faced repeated controversy after members of its board of directors, medical advisory board and several of its executives made false statements regarding their qualifications, including education and licenses.

Founder Myron Wentz was the company's chief executive officer from 1992 until 2008, when his son, Dave Wentz, succeeded him after working in positions such as president, executive vice president, and senior vice president of strategic development. In 2015, USANA announced that the chief executive officer role would be divided between Wentz and Kevin Guest, with the former taking global operations and the latter, field development and sales. Guest was appointed the sole chief executive officer in November 2016.

Operations

USANA, a multilevel marketing company, sells its products primarily through non-employee Brand Partners, as well as through the Internet. The firm's 2010 income disclosure statement defines "associates" as those who are actively building a business, acting as wholesale buyers, or are new distributors. The firm's 2009 SEC 10-K filing distinguishes between associates and preferred customers. Associates are independent distributors of USANA products and also purchase them for personal use. Preferred customers may purchase products at wholesale prices strictly for personal use and are not permitted to resell or distribute them. As of July 2011, the firm had 222,000 active Associates and 68,000 preferred customers. It manufactured 90% of its products at the Salt Lake City headquarters, which produced more than 22 million tablets each week.

Associates may be eligible to receive commissions based on their own product sales as well as through sales made by any new distributors they recruit. According to documentation from USANA corporate, 87 percent of associates fail to make enough from commissions to recover the cost of their qualifying purchases with 67 percent of all associates making no commission; the top 2.31 percent of associates earns 72.2 percent of the company's commissions. According to a 2011 article published by the Salt Lake City Tribune, the firm's FY09 income disclosure statement indicated that the average yearly income of the company's 165,710 associates, which includes those just starting, was $617, while the "top-of-the-pyramid distributors earn an average of $857,865 annually".

USANA sells nutritional, personal care, and food products through Brand Partners and online channels.

USANA classifies Brand Partners and Preferred Customers in its core nutritional business as active customers. There were 387,000 active customers as of January 2026. In 2025, Brand Partners and Preferred Customers each made up about half of all active customers.

Sponsorships

USANA has been a paid sponsor of various athletic organizations. USANA offers an "Athlete Guarantee Program" to select sponsored athletes. The program permits selected participants to enter into an agreement with the company stipulating that, should an athlete enrolled in the program test positive for a banned substance (included in World Anti-Doping Agency regulations) as a result of taking USANA products, the company will compensate the athlete up to two times his or her current annual earnings up to $1 million USD.

In 2006, USANA signed a co-sponsorship agreement with the WTA Tour and extended it in 2011. The agreement provides athletes with nutritional supplements that are guaranteed to conform to the Tour's antidoping policy. As part of the agreement in 2011, USANA donated $1 to Children's Hunger Fund for every ace scored at a WTA tournament beginning at Wimbledon and continuing through the end of the season. USANA provided its products to 40 athletes at the Turin Olympics and worked with various sports organizations, including the Professional Rodeo Cowboys Association.

In 2003, USANA became the title sponsor of the USANA Amphitheatre, an outdoor amphitheatre based in West Valley City, Utah with a seating capacity of 20,000. In May 2012, United Concerts announced a continued naming rights partnership with USANA Health Sciences through March 2018.

In 2020, USANA became the title partner of U.S. Ski & Snowboard's training and education facility, the Center of Excellence. The facility is a training hub used by Olympians, youth athletes, and various international competitions.

In the lead-up to the 2020 Summer Olympics, USANA announced partnerships with USA Swimming and the USA Skateboarding National Team. It was the official multivitamin sponsor of USA Swimming and official nutritional supplement supplier of USA Skateboarding. The partnerships reportedly extended into multi-year agreements.

Products

USANA produces three product lines: USANA Nutritionals (Cellsentials, Optimizers, and Digestion/Detox nutritional supplements), USANA Diet & Energy (Reset meal replacement shakes, protein bars, and Rev3 energy drinks), and Sensé & Celavive personal care (skin care, skin treatment, and hair & body care products).

USANA Essentials were tested in 2011 by ConsumerLab.com in its Multivitamin and Multimineral Supplements Review of 38 leading multivitamin/multimineral products sold in the U.S. and Canada. The Essentials passed ConsumerLab's test, which included testing of selected index elements, their ability to disintegrate in solution per United States Pharmacopeia guidelines, lead contamination threshold set in California Proposition 65, and meeting U.S. Food and Drug Administration (FDA) labeling requirements.

USANA began using InCelligence Technology in August 2016 and registered it as a U.S. trademark in March 2017. The technology is used in the company's CellSentials nutritional supplement system, including its Core Minerals and Vita-Antioxidant products, which USANA markets as using its InCelligence Complex to support cellular protection and renewal. As of 2019, its products are marketed in the United States, Canada, Australia, New Zealand, Hong Kong, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Netherlands, the United Kingdom, the Caribbean, Puerto Rico, Philippines, France, China, Spain, Italy, Germany, Romania, Denmark, Colombia and Indonesia.

Reception

From 2004 to 2006, USANA was named on Forbes "200 Best Small Companies" list. In 2007, a Forbes article quoted industry experts and government officials who had raised questions about the cost of USANA's supplements and its business practices. Radio-Canada later aired an investigative report that examined the company's products, pricing and "misleading income claims" made to potential associates concerning revenue. It included hidden-camera footage of recruitment and other sessions, which found one group of associates appeared to violate the company's policies and distributor agreements. This contrasted with the Canadian legal requirements for multi-level marketing companies to provide clear, frequent and complete information about the revenue of the typical participant. In addition, the same group of associates were filmed making recommendations for using USANA products to treat illnesses including leukemia.

John Cloud, senior writer for Time Magazine, evaluated nutritional supplements in which he took a regimen of USANA pills, protein bars, powder drinks and psyllium fiber as recommended by the company's online evaluation. Cloud took a blood test before starting the products to measure levels of calcium, protein, sodium, cholesterol, glucose, and other substances, and was then tested again five months after starting the supplement regimen, which included 3,000 pills at a cost of $1,200. The follow-up test revealed a change in only two values; a 75% increase in vitamin D levels (attributed to the vitamin D3 supplement Cloud had been taking) and a 28 mg/dl increase in high-density lipoprotein, which could not be accounted for. Cloud also experienced a placebo response where that act of taking the supplements made him feel more vigorous despite no physiological reasons being present. This response also led to a 10-lb weight gain, as the belief that he was more vigorous led him to make poorer dietary decisions—a phenomenon referred to as the "licensing effect".

New Zealand government statistician for the Commerce Commission, Murray H. Smith, who served as an expert witness in every pyramid scheme case brought by the Commission preceding 10 years, opined in 2008 that very few USANA distributors are likely to become wealthy, and stated, "you can make a very strong argument that this could be a pyramid scheme." When asked by the National Business Review to review the firm's business structure and compensation plan, it was Smith's opinion, from a statistical not legal standpoint, that the firm demonstrated a number of characteristics commonly occurring in pyramid schemes including that most members recoup less than what they pay to participate; that those at the top of the structure are more likely to make more than those on the bottom of the structure; and that as the company grows it will become harder to recruit others. Smith also noted the company's significant turnover in distributors making it necessary to continually recruit.

Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗

Wikidata ↗

sektorConsumer products branżaConsumer products pracownicy1 570 krajUS

Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS

06
Przychody$925M
2016-12-31 → 2026-01-03
EPS$0.58
2016-12-31 → 2026-01-03
Wolny przepływ pieniężny$9M
2016-12-31 → 2026-01-03
Marża netto-4.2%
2016-12-31 → 2026-01-03
Wycena i wskaźniki 07–12

Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?

Wskaźnik Trend 5-letni USNA średnia z 5 lat Mediana porównawcza Werdykt
P/E (TTM) -7.1średnia z 5 lat ≈19.7 ≈19.7 · ·
P/S (TTM) 0.3średnia z 5 lat ≈1.0 ≈1.0 1.2 Niedowartościowany
P/B (MRQ) 0.5średnia z 5 lat ≈2.3 ≈2.3 2.4 Niedowartościowany
Cena / FCF (TTM) -16.8średnia z 5 lat ≈20.5 ≈20.5 · ·
Cena / Przepływy pieniężne (TTM) -157.2średnia z 5 lat ≈13.5 ≈13.5 16.8 Wartość godziwa
Cena / Wartość księgowa materialna (MRQ) 0.7średnia z 5 lat ≈3.0 ≈3.0 · ·

Mediana porównawcza jest obliczana na znormalizowanej podstawie dla każdej metryki i może nie zawsze odpowiadać podstawie TTM/MRQ pokazanej dla tej akcji.

wartość · ≈ średnia z 5 lat · mediana branżowa · werdykt względem mediany

Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników

14
Średnie zaskoczenie -21.9%
Następny raport Paź 19, 2026
OkresRaportEPS ActualEPS SzacowanyNiespodzianka
30 czerwca 2026 Lip 20, 2026 $-0.07 $0.44 -116.0%
31 marca 2026 $0.61 $0.45 35.9%
31 grudnia 2025 $0.60 $0.42 43.5%
30 września 2025 $-0.15 $0.48 -131.3%
30 czerwca 2025 $0.74 $0.55 34.4%
31 marca 2025 $0.73 $0.71 2.2%

Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne

15
Rachunek zysków i strat 18
Wskaźnik Trend 202520242023202220212020201920182017201620152014
Revenue $925M$855M$921M$999M$1.19B$1.13B$1.06B$1.19B$1.05B$1.01B$918M$790M
Cost of Revenue $201M$161M$177M$194M$218M$209M$188M$201M$179M$180M$160M$141M
Gross Profit $724M$693M$744M$805M$969M$926M$873M$989M$868M$826M$759M$650M
R&D Expense $11M$12M$11M$12M$11M$11M$10M$10M$9M$9M$6M$5M
SG&A Expense $337M$263M$257M$262M$279M$261M$268M$275M$265M$234M$209M$185M
Operating Expenses $687M$627M$651M$697M$798M$749M$727M$800M$735M$687M$617M$534M
Operating Income $37M$66M$93M$108M$170M$176M$146M$188M$133M$139M$142M$116M
Interest Expense ··$262.0K$192.0K$57.0K$507.0K$66.0K$36.0K$46.0K$444.0K$15.0K$129.0K
Interest Income $2M$11M$10M$4M$3M$3M$5M$4M$2M$1M$1M$500.0K
Other Non-op $3M$-1M$7.0K$-3M$-2M$-571.0K$-335.0K$-1M$-3.0K$-1M$-174.0K$-820.0K
Pretax Income $42M$76M$102M$109M$171M$178M$150M$192M$135M$139M$143M$116M
Income Tax $30M$34M$39M$39M$54M$53M$50M$65M$72M$39M$48M$39M
Net Income $11M$42M$64M$69M$117M$125M$101M$126M$63M$100M$95M$77M
EPS (Basic) $0.58$2.20$3.31$3.60$5.78$5.89$4.44$5.24$2.57$4.14$3.72$2.90
EPS (Diluted) $0.58$2.19$3.30$3.59$5.73$5.86$4.41$5.12$2.53$3.99$3.59$2.80
Shares (Basic) 18,535,00019,103,00019,250,00019,254,00020,146,00021,156,00022,644,00024,105,00024,349,00024,185,00025,460,00026,443,000
Shares (Diluted) 18,574,00019,162,00019,345,00019,310,00020,343,00021,256,00022,818,00024,642,00024,708,00025,047,00026,355,00027,377,000
EBITDA $70M$81M$106M$121M$183M$190M$161M$205M$149M$152M$152M$125M
Bilans 26
Wskaźnik Trend 202520242023202220212020201920182017201620152014
Cash & Equivalents $158M$182M$330M$288M$240M$312M$235M$214M$247M$176M$143M$111M
Receivables $4M···········
Inventory $103M$70M$61M$67M$98M$90M$69M$82M$63M$65M$66M$45M
Prepaid Expense $23M$28M$26M$29M$27M$23M$26M$33M$30M$37M$35M$35M
Other Current Assets $5M$5M$6M$7M$4M$5M$5M$7M$5M$6M$5M$6M
Current Assets $288M$279M$418M$384M$365M$425M$329M$392M$340M$278M$244M$191M
PP&E (Net) $94M$95M$100M$98M$102M$100M$95M$92M$103M$101M$88M$71M
PP&E (Gross) ··$212M$210M$211M$199M$181M$178M$177M$164M$120M$114M
Accum. Depreciation $135M$130M$129M$125M$122M$116M$105M$96M$86M$76M$71M$64M
Goodwill $138M$144M$17M$17M$18M$17M$17M$17M$17M$17M$17M$18M
Intangibles $133M$152M$30M$32M$30M$31M$30M$32M$35M$34M$38M$41M
Other Non-current Assets $62M$59M$55M$55M$58M$62M$43M$18M$21M$22M$25M$24M
Total Assets $743M$748M$633M$597M$578M$641M$517M$554M$519M$471M$423M$351M
Accounts Payable $17M$12M$10M$11M$14M$18M$13M$10M$12M$9M$10M$8M
Accrued Liabilities $10M$14M$10M·········
Current Liabilities $129M$140M$119M$144M$161M$168M$136M$149M$141M$138M$131M$109M
Capital Leases $12M$10M$5M$8M$10M·$17M·····
Deferred Tax $5M$4M$5M$4M$7M$12M$10M$13M$14M$5M$10M$11M
Other Non-current Liabilities $23M$18M$12M$14M$14M$19M$19M$1M$1M$1M$1M$1M
Total Liabilities $157M$162M$136M·········
Common Stock $18.0K$19.0K$19.0K$19.0K$19.0K$21.0K$22.0K$24.0K$24.0K$24.0K$25.0K$13.0K
Retained Earnings $466M$479M$445M$392M$345M$383M$306M$330M$288M$265M$215M$166M
AOCI $-16M$-23M$-14M$-13M$458.0K$-4M$-14M$-10M$-1M$-12M$-4M$2M
Stockholders' Equity $533M$532M$497M$434M$395M$442M$352M$391M$363M$325M$281M$230M
Liabilities + Equity $743M$748M$633M$597M$578M$641M$517M$554M$519M$471M$423M$351M
Shares Outstanding 18,281,00019,064,00019,130,00019,206,00019,393,00021,038,00021,655,00023,567,00024,024,00024,485,00024,976,00025,266,000
Przepływy pieniężne 16
Wskaźnik Trend 202520242023202220212020201920182017201620152014
D&A $33M$15M$13M$13M$13M$14M$15M$17M$16M$13M$10M$9M
Stock-based Comp $14M$15M$15M$13M$14M$14M$16M$15M$15M$17M$11M$10M
Deferred Tax $-7M$-7M$-3M$-7M$-3M$-2M$-4M$607.0K$19M$-4M$-3M$-1M
Amort. of Intangibles $19M$2M$2M$2M$1M$1M$1M$2M$1M$2M$900.0K$431.0K
Restructuring $6M$0$0·········
Other Non-cash $-28M$-3M$-18M$15M$-20M$10M$-442.0K$-7M$10M$11M$-2M$11M
Operating Cash Flow $22M$61M$71M$104M$121M$160M$127M$152M$124M$137M$111M$105M
CapEx $14M$10M$14M$10M$13M$15M$17M$11M$13M$33M$24M$20M
Investing Cash Flow $-10M$-213M$-12M$-12M$-14M$-34M$47M$-69M$-13M$-32M$-25M$-16M
Stock Repurchased $28M$9M$12M$25M$178M$57M$150M$105M$50M$65M$61M$139M
Net Stock Activity $-28M$-9M$-12M$-25M$-178M$-57M$-150M$-105M$-50M$-65M$-61M$-139M
Financing Cash Flow $-41M$10M$-14M$-30M$-181M$-59M$-152M$-105M$-50M$-65M$-49M$-113M
Net Change in Cash $-23M$-149M$42M$48M$-72M$78M$20M$-33M$72M$32M$32M$-26M
Taxes Paid $37M$40M$42M·········
Free Cash Flow $9M$51M$56M$94M$108M$145M$110M$141M$111M$104M$88M$85M
Levered FCF ··$56M$93M$108M$145M$110M$141M$111M$104M$88M$85M
Rentowność 8
Wskaźnik Trend 202520242023202220212020201920182017201620152014
Gross Margin 78.3%81.1%80.8%80.6%81.6%81.6%82.3%83.1%82.9%82.1%82.6%82.2%
Operating Margin 4.0%7.8%10.1%10.8%14.3%15.6%13.8%15.8%12.7%13.8%15.4%14.7%
Net Margin 1.2%4.9%6.9%6.9%9.8%11.0%9.5%10.6%6.0%9.9%10.3%9.7%
Pretax Margin 4.5%8.9%11.1%10.9%14.4%15.7%14.2%16.1%12.9%13.8%15.5%14.6%
EBITDA Margin 7.6%9.5%11.5%12.1%15.4%16.8%15.2%17.2%14.2%15.1%16.5%15.8%
ROA 1.4%6.1%10.4%11.8%19.1%21.5%18.8%23.5%12.6%22.4%24.5%21.3%
ROE 2.0%7.9%13.2%16.4%29.3%30.0%30.2%30.5%17.2%33.0%37.0%31.2%
ROIC 1.9%6.9%11.7%15.8%29.4%28.0%27.8%31.7%16.9%30.8%33.5%33.4%
Płynność i wypłacalność 3
Wskaźnik Trend 202520242023202220212020201920182017201620152014
Current Ratio 2.22.03.52.72.32.52.42.62.42.01.91.8
Quick Ratio 1.21.32.82.01.51.91.71.41.81.31.11.0
Interest Coverage ··355.2560.52985.8348.12215.05232.02880.5312.29444.1900.0
Efektywność 2
Wskaźnik Trend 202520242023202220212020201920182017201620152014
Asset Turnover 1.21.21.51.71.92.02.02.22.12.32.42.2
Inventory Turnover 2.32.52.72.32.32.22.52.82.82.82.93.0
Na akcję 5
Wskaźnik Trend 202520242023202220212020201920182017201620152014
Book Value / Share $29.16$27.91$25.99$22.62$20.37$20.99$16.24$16.60$15.12$13.29$22.49$18.22
Revenue / Share $49.81$44.59$47.61$51.71$58.32$53.38$46.49$48.26$42.39$40.17$69.70$57.74
Cash Flow / Share $1.20$3.18$3.65$5.38$5.96$7.55$5.55$6.17$5.01$5.47$8.46$7.68
Cash / Share $8.66$9.53$17.27$15.02$12.37$14.83$10.84$9.09$10.29$7.18$11.47$8.80
EPS (TTM) $0.58$2.19$3.30$3.59$5.73$5.86$4.41$5.12$2.53$3.99$3.59$2.80
Stopy Wzrostu 9
Wskaźnik Trend 202520242023202220212020201920182017201620152014
Revenue YoY 8.3%-7.2%-7.8%-15.8%4.6%·······
Revenue CAGR 3Y -2.5%-10.4%-6.7%·········
Revenue CAGR 5Y -4.0%···········
EPS YoY -73.5%-33.6%-8.1%-37.4%-2.2%·······
EPS CAGR 3Y -45.5%-27.4%-17.4%·········
EPS CAGR 5Y -37.0%···········
Net Income YoY -74.4%-34.1%-8.0%-40.5%-6.5%·······
Net Income CAGR 3Y -46.3%-28.8%-20.0%·········
Net Income CAGR 5Y -38.7%···········
Wycena (TTM) 10
Wskaźnik Trend 202520242023202220212020201920182017201620152014
Revenue TTM $925M$855M$921M$999M$1.19B$1.13B$1.06B$1.19B$1.05B$1.01B$918M$790M
Net Income TTM $11M$42M$64M$69M$117M$125M$101M$126M$63M$100M$95M$77M
Market Cap $355M$680M$1.03B$1.02B$1.96B$1.62B$1.73B$2.71B$1.78B$1.50B$798M$646M
P/E 33.516.316.214.817.713.218.122.529.315.317.818.3
P/S 0.40.81.11.01.71.41.62.31.71.50.90.8
P/B 0.71.32.12.45.03.74.96.94.94.62.82.8
P / Tangible Book 1.42.92.32.75.74.1······
P / Cash Flow 15.911.214.59.816.210.113.717.814.410.97.26.1
P / FCF 41.713.418.310.918.111.215.719.316.114.49.17.6
Earnings Yield 3.0%6.1%6.2%6.8%5.7%7.6%5.5%4.5%3.4%6.5%5.6%5.5%

Najnowszy okres po lewej · wartości null pokazane jako ·

Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat

16
Wskaźnik 2026-01-032024-12-282023-12-302022-12-312022-01-01
Przychody $925M $855M $921M $999M $1.19B
Marża Brutto % 78.3% 81.1% 80.8% 80.6% 81.6%
Marża Operacyjna % 4.0% 7.8% 10.1% 10.8% 14.3%
Zysk netto $11M $42M $64M $69M $117M
Rozwodniony EPS $0.58 $2.19 $3.30 $3.59 $5.73

Właściciele instytucjonalni (13F) 151 emitentów · $260.7M łącznie · Na dzień 30 września 2026

17

Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.

Posiadacze 151
Wartość posiadanych akcji $260.7M
Nowe pozycje 25
Zamknięte pozycje 17
Aktywność instytucjonalna — Q2 2026 vs poprzedni kwartał
Nowe pozycje Zamknięte pozycje Zwiększone Zmniejszony Zmiana liczby akcji netto
25 (-5 vs poprzedni kw.) 17 (+8 vs poprzedni kw.) 60 (+21 vs poprzedni kw.) 30 (-19 vs poprzedni kw.) +1.2M

Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.

Instytucja Wartość Akcje % z śledzonych 13F Typ
BlackRock, Inc. $33 181 935 1 554 189 12,73% Akcje
PZENA INVESTMENT MANAGEMENT LLC $25 739 282 1 205 587 9,87% Akcje
RENAISSANCE TECHNOLOGIES LLC $20 464 402 958 520 7,85% Akcje
VANGUARD GROUP INC $18 340 623 934 316 7,03% Akcje
DIMENSIONAL FUND ADVISORS LP $17 878 705 837 426 6,86% Akcje
Nantahala Capital Management, LLC $17 295 080 810 074 6,63% Akcje
VANGUARD CAPITAL MANAGEMENT LLC $10 405 350 487 370 3,99% Akcje
Creative Planning $8 923 681 417 971 3,42% Akcje
AQR CAPITAL MANAGEMENT LLC $8 712 637 408 086 3,34% Akcje
VANGUARD PORTFOLIO MANAGEMENT LLC $7 758 099 363 377 2,98% Akcje
GEODE CAPITAL MANAGEMENT, LLC $6 047 019 283 165 2,32% Akcje
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $5 811 641 272 208 2,23% Akcje
STATE STREET CORP $5 577 474 261 240 2,14% Akcje
Nuveen, LLC $5 112 835 239 477 1,96% Akcje
AMERICAN CENTURY COMPANIES INC $3 999 880 187 348 1,53% Akcje
JACOBS LEVY EQUITY MANAGEMENT, INC $3 855 105 180 567 1,48% Akcje
TWO SIGMA INVESTMENTS, LP $3 533 724 165 514 1,36% Akcje
MORGAN STANLEY $3 509 150 164 363 1,35% Akcje
D. E. Shaw & Co., Inc. $3 348 427 156 835 1,28% Akcje
Allianz Asset Management GmbH $3 040 219 142 399 1,17% Akcje
BRIDGEWAY CAPITAL MANAGEMENT, LLC $2 949 567 138 153 1,13% Akcje
ALGERT GLOBAL LLC $2 813 033 131 758 1,08% Akcje
GOLDMAN SACHS GROUP INC $2 631 750 123 267 1,01% Akcje
UBS Group AG $2 474 166 115 886 0,95% Akcje
LAZARD ASSET MANAGEMENT LLC $2 077 590 97 311 0,80% Akcje
NORTHERN TRUST CORP $2 016 870 94 467 0,77% Akcje
AMERIPRISE FINANCIAL INC $1 552 893 72 735 0,60% Akcje
VANGUARD FIDUCIARY TRUST CO $1 549 540 72 578 0,59% Akcje
Vanguard Global Advisers, LLC $1 514 569 70 940 0,58% Akcje
Empowered Funds, LLC $1 499 902 70 253 0,58% Akcje
TWO SIGMA ADVISERS, LP $1 289 691 65 700 0,49% Akcje
Bank of New York Mellon Corp $1 104 521 51 734 0,42% Akcje
Quantinno Capital Management LP $1 072 261 50 223 0,41% Akcje
BANK OF AMERICA CORP /DE/ $967 539 45 318 0,37% Akcje
ROYCE & ASSOCIATES LP $884 039 41 407 0,34% Akcje
DEUTSCHE BANK AG\ $821 975 38 500 0,32% Akcje
Assenagon Asset Management S.A. $815 848 38 213 0,31% Akcje
BARCLAYS PLC $777 141 36 400 0,30% Akcje
STRS OHIO $723 765 33 900 0,28% Akcje
Skopos Labs, Inc. $673 696 38 563 0,26% Akcje
HSBC HOLDINGS PLC $672 758 31 960 0,26% Akcje
Invesco Ltd. $670 775 31 418 0,26% Akcje
SEI INVESTMENTS CO $641 513 30 047 0,25% Akcje
XTX Topco Ltd $625 320 29 289 0,24% Akcje
CITADEL ADVISORS LLC $575 617 26 961 0,22% Akcje
MILLENNIUM MANAGEMENT LLC $570 728 26 732 0,22% Akcje
Verdad Advisers, LP $556 552 26 068 0,21% Akcje
Inspire Investing, LLC $512 954 29 362 0,20% Akcje
Sanctuary Advisors, LLC $497 113 23 284 0,19% Akcje
Man Group plc $489 854 22 944 0,19% Akcje

Pokaż wszystkich 151 właścicieli instytucjonalnych →

Aktywiści i właściciele 5%+ 3 akcje

18

Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.

Zgłaszający Złożono Udział Status Cel Zgłoszenie
Gull Global Limited, Myron W. Wentz ×11 zgłoszenia 30 marca 2026 40,10% Aneks M&A / sprzedaż SEC
Gull Holdings, Ltd., Myron W. Wentz, David A. Wentz, Jacquelyn R. Wentz, Bryan Wentz, Annette Wentz, Paul & Jane Meyer Family Foundation, Paul James Meyer, Alice Jane Meyer, Centre Island Properties, Ltd., Waco Boys Club Foundation, Inc., L-K Marketing Group, LLC, Beagle Irrevocable Asset Trust 23 maja 2008 · Pierwotne zgłoszenie · SEC
Paul & Jane Meyer Family Foundation 20 maja 2008 · Pierwotne zgłoszenie Inwestycja pasywna SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Insiderzy spółki 38 insiderów · 20 dyrektorzy generalni · 13 dyrektorzy

19
Insider Rola Ostatnia aktywność Posiadane akcje Kupna 12m Sprzedaże 12m Netto 12m
Jim Brown CEO & PRESIDENT 24 lipca 2025 M 16 934 0 0 $0
Doug G Iiekking CHIEF FINANCIAL OFFICER 27 maja 2026 S 0 0 1 $-100 500
Jeffrey Yates Chief Financial Officer 28 października 2010 M 0 0 0 $0
Deborah Woo President of Asia 8 września 2016 M 1 479 0 0 $0
Fred W Cooper President and COO 28 października 2010 M 0 0 0 $0
Walter Noot CHIEF OPERATING OFFICER 27 lutego 2026 M 9 256 0 0 $0
Roy Truett Chief Operating Officer 27 lipca 2012 M 0 0 0 $0
Kathryn Michelle Armstrong CHIEF SCIENTIFIC OFFICER 25 lipca 2026 M 3 471 0 0 $0
Peter Benedict CHIEF INFORMATION OFFICER 25 lipca 2026 M 422 0 2 $-144 236
Brent Neidig CHIEF COMMERCIAL OFFICER 16 czerwca 2026 S 0 0 3 $-147 749
Paul A. Jones CHIEF PEOPLE OFFICER 8 czerwca 2026 S 0 0 2 $-231 984
Joshua Foukas CHIEF LEGAL OFFICER 7 maja 2026 S 0 0 2 $-170 336
David Mulham Mulham CHIEF SALES OFFICER 10 grudnia 2025 S 8 387 0 1 $-18 333
Daniel A. Macuga CHIEF COMMUNICATIONS OFFICER 2 maja 2024 S 0 0 0 $0
Robert A Sinnott CHIEF SCIENTIFIC OFFICER 5 marca 2024 S 0 0 0 $0
James Bramble Chief Legal Officer and Sec 5 lutego 2018 A 2 076 0 0 $0
Dave Wentz Co-C.E.O. 16 sierpnia 2016 M 384 883 0 0 $0
Rick Stambaugh Chief Information Officer 17 grudnia 2015 M 0 0 0 $0
Mark H Wilson E.V.P. of Sales 28 października 2010 M 5 000 0 0 $0
Bradford Richardson E.V.P. of Asia Pacific 25 lutego 2008 S 0 0 0 $0
Xia Ding Dyrektor 23 lipca 2026 M 8 278 0 0 $0
John Turman Fleming Dyrektor 23 lipca 2026 M 5 862 0 2 $-78 560
Peggie Pelosi Dyrektor 23 lipca 2026 M 6 061 0 0 $0
Scott J Nixon Dyrektor 23 lipca 2026 M 11 445 0 0 $0
Frederic J Winssinger Dyrektor 23 lipca 2026 M 9 733 0 1 $-38 420
Timothy E Wood Dyrektor 23 lipca 2026 M 11 837 0 0 $0
Gilbert A Fuller Dyrektor 23 lipca 2026 M 1 632 0 3 $-60 414
Robert Auciaux Dyrektor 9 maja 2022 M 8 092 0 0 $0
Feng Peng Dyrektor 28 kwietnia 2021 M 755 0 0 $0
Myron W. Wentz Dyrektor 4 lutego 2019 S 9 865 614 0 0 $0
Jerry G Mcclain Dyrektor 4 marca 2016 M 0 0 0 $0
Ronald S Poelman Dyrektor 8 lutego 2016 A 0 0 0 $0
Denis E Waitley Dyrektor 3 listopada 2006 M 0 0 0 $0
Gull Global Limited Posiadacz 10% 4 lutego 2019 S 9 865 614 0 0 $0
GULL HOLDINGS LTD Posiadacz 10% 1 kwietnia 2015 J 6 491 110 0 0 $0
Kevin Guest · 27 lutego 2026 M 45 381 0 0 $0
Donald R. Williams · 1 maja 2017 A · 0 0 $0
Doug Braun · 16 grudnia 2015 M 0 0 0 $0

Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S

Posiadanie ETF-ów Posiadane przez 22 fundusze ETF

20

Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.

Fundusz Waga Jednostki Na dzień Źródło
VFVA · VANGUARD WELLINGTON FUND 0,11% 45 046 SH 19 sierpnia 2026 Dziennie
EBIT · Harbor ETF Trust 0,07% 367 NS 31 lipca 2026 N-PORT
IWC · iShares Trust 0,04% 37 870 SH 11 września 2026 Dziennie
VDC · VANGUARD WORLD FUND 0,03% 128 565 SH 19 sierpnia 2026 Dziennie
VTWV · VANGUARD SCOTTSDALE FUNDS 0,02% 9 639 SH 19 sierpnia 2026 Dziennie
DFSV · Dimensional ETF Trust 0,02% 67 386 NS 31 lipca 2026 N-PORT
PRFZ · Invesco Exchange-Traded Fund Trust 0,01% 23 709 SH 2 października 2026 Dziennie
DFAT · Dimensional ETF Trust 0,01% 67 428 NS 31 lipca 2026 N-PORT
VTWO · VANGUARD SCOTTSDALE FUNDS 0,01% 64 278 SH 19 sierpnia 2026 Dziennie
RSSL · Global X Funds 0,01% 5 337 NS 31 lipca 2026 N-PORT
OMFS · Invesco Exchange-Traded Self-Indexe… 0,01% 1 189 SH 1 października 2026 Dziennie
DFAS · Dimensional ETF Trust 0,01% 42 099 NS 31 lipca 2026 N-PORT
IWM · iShares Trust 0,01% 283 783 SH 11 września 2026 Dziennie
DFAC · Dimensional ETF Trust 0,00% 19 278 NS 31 lipca 2026 N-PORT
ITOT · iShares Trust 0,00% 22 756 SH 11 września 2026 Dziennie
IWV · iShares Trust 0,00% 3 720 SH 3 września 2026 Dziennie
DFUS · Dimensional ETF Trust 0,00% 1 784 NS 31 lipca 2026 N-PORT
VXF · VANGUARD INDEX FUNDS 0,00% 124 681 SH 19 sierpnia 2026 Dziennie
VTI · VANGUARD INDEX FUNDS 0,00% 350 035 SH 19 sierpnia 2026 Dziennie
VTHR · VANGUARD SCOTTSDALE FUNDS 0,00% 790 SH 19 sierpnia 2026 Dziennie
IWN · iShares Trust · 101 470 SH 11 września 2026 Dziennie
SMLF · iShares Trust · 22 964 SH 11 września 2026 Dziennie

USNA Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu

21
ocena · 6 analityków SPRZEDAJ
Średni cel $25.00 +68,7%
0 0,0% Mocne kupno
0 0,0% Kup
3 50,0% Trzymaj
1 16,7% Sprzedaj
2 33,3% Mocna sprzedaż

12-miesięczny cel cenowy

1 analityków · 2026-10-01

Średnia cel $25.00 +68,7%

Niski$25.00 Średnia$25.00 Wysoki$25.00

Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora

22

Podstawa R/R, ceny według zamknięcia z ostatniego końca roku obrotowego każdej spółki.

Ticker Kapitalizacja Rynkowa P/E Przychody r/r Marża Netto ROE Marża brutto
USNA $355M 33.5 8.3% 1.2% 2.0% 78.3%
EPC $946M 38.4 -1.3% 1.1% 1.7% 41.6%
BRBR $4.39B 21.6 16.1% 9.3% -72.0% 33.3%
HNST $291M -18.4 -1.9% -4.2% -8.8% 33.3%
NUS · 3.0 -14.3% 10.8% 22.0% 69.5%
NAGE $507M 31.8 29.9% 13.4% 24.7% 64.3%
NATR $378M 20.4 5.7% 4.1% 12.0% 72.4%
MED $117M -6.3 -36.0% -4.8% -9.0% 71.3%

Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów

26

Wybierz wskaźniki, które są dla Ciebie ważne — kliknij + obok dowolnego wiersza w sekcji Pełne dane fundamentalne powyżej.

Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.

Źródło: SEC 10-Q złożone Sie 13, 2026